Nabilone Could Treat Chorea and Irritability in Huntington’s Disease

SIR: Huntington’s disease causes chorea and psychiatric abnormalities. Psychiatric symptoms were found in one study in 51 out of 52 patients. Dysphoria, agitation, irritability, apathy, and anxiety were found in above 50% of the patients sampled.

Many sources postulate that cannabinoids might have a neuroprotective effect which could delay the onset of symptoms by delaying or preventing the death of striatal neurons. This neuroprotective effect has also been postulated by other sources.

To date there are only two reports on the use of cannabinoids in Huntington’s disease in the literature. Cannabidiol, a nonpsychotropic cannabinoid, had no effect on chorea severity in 15 patients. In one single patient, single dose, uncontrolled open clinical trial using nabilone, 1.5mg, the chorea increased significantly. We present a case of a female patient with irritability, which improved after the introduction of cannabis. This improvement was maintained by treatment with nabilone.

Comment
This patient met DSM-IV criteria for NMS. The cognitive deficits seen in this patient following NMS are reminiscent of an organic amnestic disorder, a rare entity described in patients recovering from NMS. Of interest, among all the cognitive domains, memory impairment is the only one that has been consistently reported on recovery from NMS. Whether the concurrent urinary tract infection and the resultant delirium could have contributed to this presentation cannot be entirely ruled out. However, this seems less likely as this patient continued to exhibit cognitive deficits long after recovery from the urinary tract infection. Moreover, the Physicians’ Desk Reference does not suggest any association of norfloxacin with cognitive deficits. Some investigators have speculated that these persistent deficits may be a consequence of complications of NMS, such as prolonged hypoxia and extreme hyperthermia. This is supported by reports of memory deficit as a neuropsychological sequela of heat stroke. In conclusion, more research is encouraged to explore why memory is preferentially involved in NMS. Excitotoxicity due to glutamate surge has been implicated in ECT-induced memory dysfunction, and glutamate has also been hypothesized to play a role in NMS. Thus, it would be interesting to decipher the role of this neurotransmitter in long-term cognitive sequelae of NMS.

D.N. MENDHEKAR, M.D., D.P.M.
Delhi, India

HARPREET S. DUGGAL, M.D., D.P.M.
Herrick Memorial Hospital, Tecumseh, Mich

References

Nabilone Could Treat Chorea and Irritability in Huntington’s Disease

SIR: Huntington’s disease causes chorea and psychiatric abnormalities. Psychiatric symptoms were found in one study in 51 out of 52 patients. Dysphoria, agitation, irritability, apathy, and anxiety were found in above 50% of the patients sampled.

Many sources postulate that cannabinoids could have a beneficial effect on the symptoms of Huntington’s disease, especially on choreatic movements. As well as providing possible symptomatic relief in Huntington’s disease, there is also some evidence that cannabinoids might have a neuroprotective effect which could delay the onset of symptoms by delaying or preventing the death of striatal neurons. This neuroprotective effect has also been postulated by other sources.

To date there are only two reports on the use of cannabinoids in Huntington’s disease in the literature. Cannabidiol, a nonpsychotropic cannabinoid, had no effect on chorea severity in 15 patients. In one single patient, single dose, uncontrolled open clinical trial using nabilone, 1.5mg, the chorea increased significantly. We present a case of a female patient with irritability, which improved after the introduction of cannabis. This improvement was maintained by treatment with nabilone.

Comment
This patient met DSM-IV criteria for NMS. The cognitive deficits seen in this patient following NMS are reminiscent of an organic amnestic disorder, a rare entity described in patients recovering from NMS. Of interest, among all the cognitive domains, memory impairment is the only one that has been consistently reported on recovery from NMS. Whether the concurrent urinary tract infection and the resultant delirium could have contributed to this presentation cannot be entirely ruled out. However, this seems less likely as this patient continued to exhibit cognitive deficits long after recovery from the urinary tract infection. Moreover, the Physicians’ Desk Reference does not suggest any association of norfloxacin with cognitive deficits. Some investigators have speculated that these persistent deficits may be a consequence of complications of NMS, such as prolonged hypoxia and extreme hyperthermia. This is supported by reports of memory deficit as a neuropsychological sequela of heat stroke. In conclusion, more research is encouraged to explore why memory is preferentially involved in NMS. Excitotoxicity due to glutamate surge has been implicated in ECT-induced memory dysfunction, and glutamate has also been hypothesized to play a role in NMS. Thus, it would be interesting to decipher the role of this neurotransmitter in long-term cognitive sequelae of NMS.

D.N. MENDHEKAR, M.D., D.P.M.
Delhi, India

HARPREET S. DUGGAL, M.D., D.P.M.
Herrick Memorial Hospital, Tecumseh, Mich

References

Nabilone Could Treat Chorea and Irritability in Huntington’s Disease

SIR: Huntington’s disease causes chorea and psychiatric abnormalities. Psychiatric symptoms were found in one study in 51 out of 52 patients. Dysphoria, agitation, irritability, apathy, and anxiety were found in above 50% of the patients sampled.

Many sources postulate that cannabinoids could have a beneficial effect on the symptoms of Huntington’s disease, especially on choreatic movements. As well as providing possible symptomatic relief in Huntington’s disease, there is also some evidence that cannabinoids might have a neuroprotective effect which could delay the onset of symptoms by delaying or preventing the death of striatal neurons. This neuroprotective effect has also been postulated by other sources.

To date there are only two reports on the use of cannabinoids in Huntington’s disease in the literature. Cannabidiol, a nonpsychotropic cannabinoid, had no effect on chorea severity in 15 patients. In one single patient, single dose, uncontrolled open clinical trial using nabilone, 1.5mg, the chorea increased significantly. We present a case of a female patient with irritability, which improved after the introduction of cannabis. This improvement was maintained by treatment with nabilone.

Comment
This patient met DSM-IV criteria for NMS. The cognitive deficits seen in this patient following NMS are reminiscent of an organic amnestic disorder, a rare entity described in patients recovering from NMS. Of interest, among all the cognitive domains, memory impairment is the only one that has been consistently reported on recovery from NMS. Whether the concurrent urinary tract infection and the resultant delirium could have contributed to this presentation cannot be entirely ruled out. However, this seems less likely as this patient continued to exhibit cognitive deficits long after recovery from the urinary tract infection. Moreover, the Physicians’ Desk Reference does not suggest any association of norfloxacin with cognitive deficits. Some investigators have speculated that these persistent deficits may be a consequence of complications of NMS, such as prolonged hypoxia and extreme hyperthermia. This is supported by reports of memory deficit as a neuropsychological sequela of heat stroke. In conclusion, more research is encouraged to explore why memory is preferentially involved in NMS. Excitotoxicity due to glutamate surge has been implicated in ECT-induced memory dysfunction, and glutamate has also been hypothesized to play a role in NMS. Thus, it would be interesting to decipher the role of this neurotransmitter in long-term cognitive sequelae of NMS.

D.N. MENDHEKAR, M.D., D.P.M.
Delhi, India

HARPREET S. DUGGAL, M.D., D.P.M.
Herrick Memorial Hospital, Tecumseh, Mich

References
A 32-year-old married man presented with bilateral blepharospasms that lasted for 1 to 2 minutes. The spasms were provoked by light, embarrassment, and fatigue. The spasms would disappear in the later stages of the disease. However both the husband and the staff were sure that the introduction of cannabis was beneficial and greatly improved the patient’s quality of life in her last years. There is need for further trials to establish the therapeutic use of cannabinoids in the symptomatic treatment of Huntington’s disease.

The first author receives an unrestricted educational grant from Cambridge Laboratories, which holds the European marketing rights for nabilone.

**ADRIENNE CURTIS, B.A., B.Sc. HUGH RICKARDS, M.D., M.R.C.Psych.**
Department of Psychiatry, University of Birmingham, Birmingham, United Kingdom

**References**


**Essential Blepharospasm Responding to Haloperidol**

SIR: Blepharospasm is a disorder of adulthood that is more common in women. It presents as a sudden involuntary bilateral eye closure that is often exacerbated by air pollution, wind, exposure to bright light, movement, and stress. However, to date it is not possible to correlate it with any psychopathology. If it presents as an isolated blepharospasm in adults, it is better termed as essential blepharospasm. It must be differentiated from Meige’s syndrome which includes oromandibular dystonia along with blepharospasm.

Below we describe a case of essential blepharospasm that responded to low doses of haloperidol but not to other drugs.

**Case Report**

A 32-year-old married man presented with bilateral blepharospasms that lasted for 1 to 2 minutes. The spasms were provoked by light, embarrassment, and fatigue. The spasms would disappear in sleep. These complaints were of 5-month duration.

There was no history of any chronic physical illness including neurological illnesses such as Parkinsonism, Wilson’s disease, epilepsy, stroke, nor a history of ocular pathology (e.g., blepharitis, conjunctivitis or iritis), any psychiatric illness, any psychiatric or other drug. The patient was treated with a single regimen of nabilone, a synthetic 9-keto cannabinoid, which the patient began taking, 1mg each day. The husband and the nursing home staff both reported improvements in behavior and reduction of chorea coinciding with the introduction of cannabis and maintained by daily taking nabilone.

**Comment**

This report has many limitations. It is a single case report and no measurements were taken at the time of the introduction of cannabis and nabilone. The information was obtained by interviewing the husband and staff from the care home in 2005. The symptoms of Huntington’s disease do change over time and the movements are different in the later stages of the disease. However both the husband and the staff are sure that the introduction of cannabis was beneficial and greatly improved the patient’s quality of life in her last years. There is need for further trials to establish the therapeutic use of cannabinoids in the symptomatic treatment of Huntington’s disease.